Platis Odysseas, Anagnostopoulos Georgios, Farmaki Kallisteni, Posantzis Markos, Gotsis Efstathios, Tolis Georgios
Thalassaemia Unit, General Hospital of Corinth, 53, Athens Avenue, 20100 Corinth, Greece.
Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:279-81.
Thalassaemic patients with haemocromatosis often present with metabolic disturbances such as diabetes mellitus. A group of adult thalassaemic patients who received intensive oral and subcutaneous chelation therapy (Defferiprone/Ferriprox and Desferioxamine/Desferal) for a period of 24-36 months was studied for the presence of glucose metabolism disturbances (GMD). Investigation of the prevalence of diabetes mellitus (DM) and impaired glucose tolerance (IGT) was carried out by yearly oral glucose tolerance tests (OGTT). Results showed that GMD (DM and IGT) improved in 1/3 of the patients after the intensive combined chelation treatment, a finding that we attributed to a reduction in liver iron deposits. Although this study is still in progress we believe that intensive combined chelation therapy may have a positive effect on glucose metabolism.
患有血色素沉着症的地中海贫血患者常出现如糖尿病等代谢紊乱。对一组接受了24至36个月强化口服和皮下螯合疗法(去铁酮/铁普罗克斯和去铁胺/地拉罗司)的成年地中海贫血患者进行了葡萄糖代谢紊乱(GMD)情况研究。通过每年的口服葡萄糖耐量试验(OGTT)来调查糖尿病(DM)和糖耐量受损(IGT)的患病率。结果显示,强化联合螯合治疗后,三分之一的患者葡萄糖代谢紊乱(糖尿病和糖耐量受损)情况有所改善,我们将这一发现归因于肝脏铁沉积的减少。尽管这项研究仍在进行中,但我们认为强化联合螯合疗法可能对葡萄糖代谢有积极影响。